ESTRO 2024 - Abstract Book

S5707

RTT - Patient experience and quality of life

ESTRO 2024

Conclusion:

This analysis showed a 39% recruitment rate, with 35% of patients ineligible as they lacked a smartphone. Participants described the ScanWatch as easy to use and comfortable. Smartwatches could potentially facilitate cardiac monitoring of patients following radiotherapy and inform future research. However, exploiting mobile technology within this patient group may be impeded by a digital divide. This exemplar study has allowed for up skilling of the radiotherapy clinical trials team at our institution. The procedures and documents developed for ReCoRd have formed the foundation to support further clinical trials and studies where the team hold primary responsibility. Further analyses are pending aiming to report on the ECG findings.

Keywords: Smart technology, cardiac monitoring, thoracic

2596

Proffered Paper

Living with Oligometastases: Preliminary PROs & QoL in the SOFT MR-Guided SABR Multicenter Trial